<?xml version="1.0" encoding="UTF-8"?>
<supplementary-material content-type="local-data">
 <p>Supplementary material for this article is available at 
  <ext-link ext-link-type="uri" xlink:href="http://advances.sciencemag.org/cgi/content/full/6/6/eaax7989/DC1" xmlns:xlink="http://www.w3.org/1999/xlink">http://advances.sciencemag.org/cgi/content/full/6/6/eaax7989/DC1</ext-link>
 </p>
 <p>Fig. S1. DENV2 NS2A suppresses RNAi in S2 cells.</p>
 <p>Fig. S2. DENV2 NS2A has dsRNA-binding activity that is required to suppress Dicer cleavage in vitro.</p>
 <p>Fig. S3. The analyses of DENV2-derived vsiRNAs in 293T-IFNAR1-KO cells.</p>
 <p>Fig. S4. VSR deficiency causes replication and infection defects in DENV2-infected mice.</p>
 <p>Fig. S5. The knockdown of aaDicer2 and aaAGO2 in Aag2 cells and the conserved active site residues among different AGO proteins.</p>
 <p>Fig. S6. NS2As from the four DENV serotypes suppress RNAi in S2 and Aag2 cells.</p>
 <p>Fig. S7. Flaviviral NS2As suppress RNAi in 293T cells.</p>
 <p>Fig. S8. JEV NS2A inhibits antiviral RNAi in both mosquito and human somatic cells.</p>
 <p>Table S1. Profiles of vsRNAs.</p>
 <p>Table S2. The primers used in this study.</p>
</supplementary-material>
